Researchers have found several characteristics identified on PET/CT that may help to predict early clinical failure of untreated follicular lymphoma.
A recent study in JAMA Dermatology evaluated overall and leukemia-specific survival in patients with AML and leukemia cutis vs AML alone.
The authors explored the evidence supporting the safety and side effect profile of enasidenib, FDA-approved in August 2017 for relapsed/refractory AML.
Researchers tested the addition of the T cell–boosting decitabine to anti–PD-1 therapy with camrelizumab among patients with relapsed or refractory classic Hodgkin lymphoma.
The MYD88 driver mutation was detected in the cerebrospinal fluid of a majority of patients with CNS lymphoma, indicating its potential utility as a diagnostic and monitoring tool.
Researchers looked at the treatment failure rate for immunotherapy with R-CHOP in patients with diffuse large B-cell lymphoma who were occupationally exposed to pesticides.
A phase III trial evaluated intermediate-dose cytarabine plus granulocyte-colony stimulating factor (G-CSF) vs G-CSF alone prior to autoSCT in multiple myeloma.
A 39-year-old woman with no significant medical history presented to the emergency department with progressive diffuse abdominal pain, involuntary weight loss, anemic syndrome, and limitation of mobility. What is the best treatment course to follow?
Researchers compared the newly developed PRIMA-PI risk score against FLIPI and FLIPI-2 in patients with follicular lymphoma.
Researchers tested the combination of isatuximab with dexamethasone and pomalidomide in patients with relapsed or refractory multiple myeloma.